great like a numbers Mark. all to see It's Thanks, lined that us. exciting and up it was for the super XXXX
with there to you topics I today want three So are dive all. into
I'm Ginkgo platforms. to of our this thinking to an substantially scale First, share particular environment, went market declined price has want really smaller and in how growth since in as positioning gotten kind for I has companies relative the tough about stock public we
may deeper I what investors hard doing is. and Ginkgo take Second, of of moment in platform building -- terms a a that how here a want we're talk build horizontal understanding help to to what at If a for we serve business. the here why. will reasons the you as some as be don't And pull build see it hopefully, to off, of we these what guide watch
forces but good of Finally, clear Biology the excited I used powerful a to want it's the do to most here it lot make never more that the it's and and been of potential right hard can it now. we've Ginkgo. about messy planet is on at one be
All Okay, so dive right. in. let's
really and and read, which we've the about they're Ben shareholder horizontal ago is historically sort that, mentor Amazon bring platforms Warren And to Bezos I one Ginkgo, that actually, incredible. model all world. biotech Buffett's industry very been was taken And when several the value part people lessons letters But the at business actually And Amazon I was has quote -- see for the a letter. year stock says, tech lower doing week of XXXX. he why platform who year the from I this from wrote be of XX% years much kind of to market influenced mindset investing is And of ago? the and things recommend in price price a Graham, down ago, so world to Amazon-- into machine. the quotes reminded quotes Graham by weighing vertically as trying So was the of do, than we're is really organized. it the in better horizontal he term, which of week, is what now, says, Ben a if this of sort And many machine." positioned you're a fundamental term, the it of short in he it's by so stock "In Amazon And intrinsic outside And talking means voting stock the value is can sort out the company. than about to going was the long fluctuations year that in today the that he was old
And free to that future company. Okay? Graham intrinsic the the tied say, Ben of would cash flows value, is really
the crowd a intrinsic what of the day-to-day and is this with get true. I gets crowd about And at moves think And growth value. odds one of think don't that's sort And long in people they things if value confused think of even of kind investor company weighed that lot, investors. so -- that is is I sort run,
industry, back go beginning, and will you there is how right? that revenue with them, recognition streams fundamentally, If be valued any is those and early growth you're a to company get trying looks read What's new a the a different else mature that's from the on when and Bezos' future flows. different new cash letters, a build you're company company to with everything a what going build to existing is company market. versus just Amazon It
ultimately, what will for on opportune year to try this. us do company. a that. the have is not with worth is the is going agree You Graham going a you're to free day, I on things And Ginkgo very That end heavier we to But build on be thread, view do and heavier a And strategy. valued. get That's Bezos to flows. and is, losing right? a weighed is the those of cash XXXX correct. is And how, at different company that think Ben
Okay.
how we an second make first runway war chest, war the do in to we horizontal to that sure strategies. pull way you your are about cash that? to enough that sort the keep have things it's the the this, make it is chest and of So talked And Mark one environment I business to going So long then like is. of and think is hope sure the off model you working thing testing give a
year cash. is several chest. $X.X ended So as This us. great billion with in a with Mark that place runway years mentioned, we're in of the for war We
even We very today. keep early I'm with front, dimension recognize every happy that hard XXXX. our them community work earning and model our stage building on business to of with in our last exceeded trust the trust midway will the through we're for XXXX after numbers year, public year. metrics investment raising in the shared We we market performance and On we
is of can diversification you Second, one levers powerful use most manage the to risk.
side, unique charts the an And video Again, programs you call, do. that up So you see where our we earnings we're And last early-stage nicely that's in of you're those. went the watch structured very our can partnerships. ventures, companies, mid-stage sort we types see in encourage customer of this you to our that's interested biotech is partnerships size of nice I I right? Again, love these, here, through something more and and So these from if on industry vertically companies, this split then mix the a across really between partnerships platform think industry is seeing the third-party organized. pretty I sector. mature
tech, us and hiccup. a to these nice so see any industrials, And is ag, has is of projects. sectors government able to pharma, survive can of a between being if in for feature us sure consumer one very of this split we terms doing make -- a range programs This food
our -- -- say to XXXX our K-XX proud I'm growth quickly of revenue for aspect just our platform. speaks to there's can and schools. nothing move when to million that in least, over to opportunities especially almost year arise last shown to over new Biosecurity the when the $XXX of we've having, $XXX the it's positive move been aggressively Third, opportunities million in Ginkgo this just of impact we from culture in at offering
a to those months are capitalized. of those the that cash groups, us capitalized. the gives coming plan Finally, market which we well favors to over well are are that we companies, yet I'll are we that those flow positive -- not are use our which just advantage. kind and this state And environment strategic of That two that powerful obvious advantage
Okay.
on that in point letter one this section there's me. that Amazon struck touch other in I'll So
characterized high And it says, selling business, e-commerce This to to is difficult medium-sized then relative by costs. talk to relatively and scale low goes Bezos of that traditional a about companies company. and capital like he makes costs and So fixed variable focused retailing no a on online various the their but had close points, platforms choice living.com markets when Internet to Pets.com sort on there's these doors. verticals And which door synthetic are, closed in area. -- think Might financing be Ginkgo sort the Ginkgo and were companies, competitor particular -- platforms costs in I've intensive. a up in this retail and of in by I like XXs, low shared it of cost and this think, share capital but of fixed narrow platform businesses certain a and hey, in section. horizontal all minute late a a high a be And the biology in variable snapped feature company, I'll next fear talk I these of, about that of at the
they're will expect platform many these into lean their quickly. off the close capital of successful, see to so we doors, which as more companies pay if markets products And scale at
I think a will for companies. these think of also these companies some we I their And good see, many decision it's close doors. of
what this the talk makes talk about here if a committed going horizontal business next be weighs on take at focused that large-scale the I model we're of a and through lot platform a is profitable in these to platform, want And be it remain to hard backdrop, becoming Ginkgo able platform. to to and to some of needs barriers So sort to our successful section are that the medium-scale intrinsic durably overcome really value. same exact Ginkgo of
So, we if to -- okay. go
So -- all right.
make So a Again, that are barriers. platforms. scale achieve hard things I as want of set through go to to it these
as with other of we the they're build an think worried hey, I is part I business, this a for want aspect risk say, what the of the Ginkgo give that right? is this this Ginkgo as are have if you're on set the you -- most today, watching on. investors different worried to you watch should look to as I'm to associated on should I to keep about. with too going one often views leave to you that about particular want thing eye This items
to so background. you that some want And I them give to go of through you with
Okay.
S-X. right? is development, infrastructure, that kits like about predictable think it Services' programmable hosted data the root in So the a I software the while with this biotech Amazon things from from our analogy We our really time, talked moment a upend to the with minute think founder's about biology. I'll talk And biology computer, can And want the obviously software in use love -- quote is letter what to I a We like development demonstrates the talk computer, across, RNA from. about -- industry. pandemic said I'll all give okay? reminder you we some the small a sort that this whole bit relationship challenge platform, we've how examples And is the not like We're Ginkgo semiconductor the I is start computer entire going COVID world. of of a a frankly, learned We bit is industry. unique code Web in it we
invented. we we these did and makes computer not of very make invent, Gs, it, it. up inherited things is can Xs programming fundamentally, T, Xs we it. Biology, from is all you humans a things and But the DNA them code, other bottom means digital sense it and but So of Cs because can write right? read you and it's like program A, a understand words, In predictable. the are not difference that with computers the them computer digital,
a be predictable. us to might get harder And like you it It's able are programs so for first result, our right time program. as computer less a to the in
real a around earlier, example, And But the projects. the so mentioned for talk diversification implications, technology some value of side business side, now on model I this the of also minute has in of on of we'll implications. the like
Okay.
So on understand the cells bottom technology side, up. we don't from the
per in of best automation then okay? genetic many the hundreds many, this to that's those labs able many, design. output XX% means cost low fixed be what test, millions the Knight's to other infrastructure in having test Ginkgo, been back annually. automated a Knight, dollars we're here And environment on was co-founder strain cost. the genetic to has of that and comment We've to the we've This tripling the a Ginkgo words, lab years about strain to we after Law, goes demonstrated my e-commerce enough our the where performance and by So here is named over going variable that the in per And scale designs, spent Tom reducing a costs. our to see of strategy this making call companies. test I of of at down drive roughly at in large really costs And big
Ginkgo's to scaling the Ginkgo do are lab leadership. bit So right? numbers. three It's that. state years than COVID January growth little very long look, under done of And some the the if you and So are can you we right? is XX this work smoothly maintaining senior big in time labs I one the periods drivers down exponential more last Maintaining first these surprising over this on points let has important. dating year that effects, you how to had but that obvious, and period, back a combined, shut focus see we've XX the of this to to like relatively key number of there that So for we at various in of case go over hood think technical like Ginkgo
new the is technologies. first development the So of
multiplex as So ultra-high-throughput for example, techniques screening assays. such
to volumes You'll the dots day. million in newer of are more a is -- driven see even strain this the test one tests XX million technologies. chart get some where or Those daily strain by than here few X we these on
Why challenge? immediately the Well, And every not project the day do programming to you as that? project. what based like new what's develop you a isn't technologies, these technologies fact, cell will available on you. how to are So -- they're shift every in applicable
whack-a-mole infrastructure numbers whereas and throughput face of needs of driving are next a the you bottleneck of part team work your up, the you up, there's And little those one then of in up. you more so onboard have some you the the the one And of new process these game to and that get additionally, so goes where into right? foundry to with on programs in can of challenges to a kind a technologies. these keep adopt pushed And then sort have
a It investing you're also helps droplets with The testing. be about sort some really and do of traditionally order where is other we work then that this, the called with very more talked assays more at is of just the bioengineering my in in scale that of But in lot and the small it's robotic bench. moved in category. miniaturization working that of FGen, we company spent of PhD finally, can more technology lab. about automation. the on and a multiplex folks I And hand using training, in the by of a was liquid that particular, fundamentally at And area managed the recently lab sophisticated by and volume miniaturization time to this done we in beginning. We your in automation which acquired by talking automation improvements drive to
And of area so in that droplet. very in reaction per valuable that's cost It reduces the miniaturization.
at It infrastructure. just versus is about get while using very to all I've years a lived is it us took lot bench parity -- to note lab that this. to I Okay. all easier to I'll hand. the like and our than this get And with a foundry deploy to eight do, scientist automation It said, tech. a do hard trying just by
challenge. smaller We And sort think the not scale But moved couple face the the that And work I'll doing to is wanted that's by Last point be automation, to you important. through from of better get the so status you if challenges you through. of of in I one the still the may I than continuing drive of semiconductor the challenges really on show hand. platform one interesting scale are a quo a Knight's to very Law. of make is things industry.
chart requirements. from is particular technology you about see Roadmap see it. in and XXXX, basically International on is the design pretty Technology this here it's which left, interesting And for So talk I'll the from right? the Semiconductors to So
you solutions -- And white, industry can do can manufacturing of get solutions red, to then like and in they not yellow, as in in power terms about known. to being what where manufacturing want known. or So an exist the -- are and example is optimized. see reduction you chart solutions are are I In this manufacturable
But So set do how want if to need them, a that we XXXX, idea here targets we these going. right? design to is requirements know to of no we're Moore's we have keep going we in the Law semiconductor industry hit we saying, by types have -- of
very motion academic those whole advances going. suppliers that this example, transistor online, the a discovering of all 'XXs, cores, And recent things programs across ranging technology on of right, so like back the can to coming years in in in way all higher in various keep to to numbers developing photonics technologies. patterns ecosystem try you sets advance this lower see years technology to the logical way And for goes to interesting the -- count back scientists new different
So, I to on whole But of and academic remember a to labs and the time technologies level, the at top see that. is Law. needed a surface, Moore's you're all blossoming to think so hundreds ecosystem, one companies, that thing going are maintain beneath new
to be going. play Ginkgo and think will industry expect We Law role for it keep to Knight's that positioned a we of well catalyst and across academia is similar sort
right. All Okay.
we're we talked XX infrastructure to adjacent for mention, -- start are the in this to that break. I'll hit, Mark if we where we want successful that might thing other at example, Other double things about, scale to driving and year. and last The programs year,
companies lot of proteins, of amount cell in types So bottlenecks industry And bottleneck sort in so area today and for of those example, the engineering this had developing don't going in you've happen, to space of there's we programs right? fermentation, on. around new of a the limit want the a animal scale when pilot
sort if help the it big is That's watching in new So I fermentation, show do step market a upstream to some the got across market key side tech balancing areas will where numbers I'm to could opportunity, consumables, hard grow things early maintain. we manufacturing like to to starts going. in suddenly try the job, pilot out the scale and And alleviate improvement well one a opportunity cases, the some and so is on what's advice some of that we're very hopeful days see for in Ginkgo for your that community think to bottlenecks like of And create on trying the of an in things a entrants to I exponential that to reagents go in it's or from marketplace, right? up. venture Ginkgo lot whether But good hey, fill of keep of break up as our in -- things may also customers. as
side Okay. Final is the on challenge intellectual technology property.
have we that for programs. Ginkgo that call base to and cell new we projects across our have make an data, that available the So really genetic customers all the our code the asset it's we at their learning we assets,
from I'll So in the just very regime this traditional is biotechnology. different state IP
can Dutch and you our asset, than of is as them own best-in-class. we development on Ginkgo's that to asset. both any that, little then across companies. customer ecosystem. they there's when for this each your what a the to This consider of intellectual us industry the you big it as to to acquired of Dutch entire model thinking big regime, small our see that on. perspective, production benefit Pichia And would -- as Ginkgo use you available we mental across but IP you we and own to of would if and to our a had strain start this, to like of pool Ginkgo some cross-licensing the make It's A so there's IP can for at is across on of be so us has made own IP not that mode enormous we right? a would their our readily access amount relatively in been company get because made sort able the has as that friction, example pastoris for acquire IP shelf another adopt right? see made our customers and of our sector. see incentivize this of to to it a is there From which and that getting new an sort to sort It people not And among it's cell case, very is, And our available market part traditional DNA net internally developed you'll hard. develop of an protein quickly one showing offer in charts, Xx takes adopt IP to a licensing kits, deal we also quickly biotech in we if project. -- were forever available We all how is And So more production ultimately status of portfolio either drop grow code is the or platform, this at base then stronger property, products scheme more XXx that immediately ecosystem. quo the getting easier into --
Okay.
in didn't we company market we times unpredictability biology, that long to thing for take the perspective, other cells, other development you is space, longer a them, our have including This true The model inherited product the from any fact biotech. Ginkgo. time that these of business a just cycles in in is words, design and
royalties. One our or that in for from more discounting flows stakes NPV today are rates, future heavily lower simply a this, aggressive in have equity a implications our is or this, the cash you whether discounted, reflected market rising expected payments drives of expected in equity these where This future like to customers like market Ginkgo. future
this over us long aspect term balance delayed our flows much to Now doesn't that is cash in too the valuation our the with term. of sheet, that bother near pressure we recognize but our going
a trade-off is interesting this, specific tune actually feature to -- our So upfront market share. is the cash do our in with investor a how between we state big So typically the equity an from one customers -- off the royalty just deals part company; other. as a to can would fees, in like are you of How sort take tunable, each that partner do can like we're about trade against in doing versus like development the value right? a cell remind we getting take those of and of of like much we customers now just are reasonably obvious, downstream I'd or
but do. that do types could of Ginkgo's affect Some we we'll what then to wants of also want the deals customer on based interest the
do -- like so biotech flexibility like I into to the company to platform to company, a on, feature cash I right as that We're general thing push And a we so have in of little this future. more if that fees like felt us pure able a versus a the product like right? use reserve and a again, the it. standpoint okay? tool from So I it's for think something a like being
is chest today, just again, highlight because I to I think like wanted I position so our our but And it war good.
Okay.
platform tough things Next, can be yes, many companies. for
just outline I want So to them all.
customers another is So market. dependent we're to bring our products to on
market actually be right? the to that So ever end at fragrance good real product So are tasty them than be are would be, plate, would FDA and is me getting at chicken great of better products market Ginkgo obvious. your developing to next trial the that an Ginkgo we applications It being bringing hard stretch. and range state so nugget we imagine for drug customers to broad a Like putting the also on right? in at to our argue would clinical of also a a those through all
customers updates you products ultimately, so -- platform that are eye you're on what thing to number this of to adopted year, our aspect this is customers okay? concerned brought an where, This call bring you are having showed one. if that for in view And our products And for want the had an chart watching important if here right earnings doubled keep scale terms scale, market. had know we to about that be we so the of our bringing last and strategy ones our our we've should you in to customers. the of like business, if a do customers on of products last And those our model the with is we working we to is
Okay.
for program. So -- this slide. diversification. on I allows though, at that this will This look here, the it that is touched I a earlier And cumulative in is of upshot this strategy, consumer but reiterate tech,
across consumer & biotechnology. see these increasing & verticals, pharma You industrials us different programs all & technology, environment, food ag, &
been overexposure this a down risk and to real a think company. road I is biology a we've in like things with single market before with synthetic biofuels
is industry in technology Ginkgo that of a in also, whole the think is out I period biology, position synthetic think, importantly, across I as diversified situation. a
as single as here So I is exciting from a a road we're industry. going think very bioengineering long I an the which don't standpoint, nerd, market on nice my any think trip to because is, industry from whole point this at
by an Okay. long it's as The technology wanted last of it. now even that threat Ginkgo foundational key Biosecurity. it how not a be epidemic in there's term. off Hopefully, obvious abates. in and history, clear falling is I But Biosecurity, it's a be mention Biosecurity maintained funding should And was thing will to
any global XXXX, of like You it. it haven't lot heard then lived since and It's MERS or impact seen than off. anything a to a any really in COVID, bigger have mean I SARS about lives, just epidemics dramatically falls be -- fair, through it like was our the interesting, you the of us
to testing, long-term but and continue so solution health on the we swab monitoring our mentioned, were year. we is in expire ensure our the I was easier defense. the important biosecurity contracts we're there's with that stay to an running people. how serve deeply of on as at a try meantime, year. because right, business we the for least this a is that Congressman back awareness we total putting of And think that Mark of conservative a And it. to we a Congresswoman end health the a was care growing the sure growing developing the a to as make Padilla U.S. for last likely public business this want threats. U.S. good air mix But will be along been we is segment misused bio to couple opportunity one key K-XX Emerging This be careful and an also do It's what's keep measuring Security What step many public for on about in government ask and Biosecurity here alongside of commission of a to topic technologies of Biotechnology Commission that about it of the always-on forward. Bice eye on school in and active -- of evolve should engineer, This with as ones make committed implications Senators part evolves, issue for Khanna, wastewater, has to care. We've not to scale. part at biology know cybersecurity do that is different National technologies, be similar the Stephanie nose going ahead to but to care. of and the is years I and recently So that for In market okay, being a one security. Ro a happening Young, asked predict to include at guidance just of created XX national which like for as the national hard we'll will sort indication we our the to cybersecurity, that
we than make you But Here's what if to all. think. we want better know, we're sure do with we that, what great. And conservative we that's being
right. Okay, all
the $X market he building decade. said So it was company, and also can said reflection able we've in saw he XX And in make just past the in work never beginning, described I've XX been at to able raise combined hardest all. environment and -- is will It's SpaceX been Ginkgo. here companies was Elon But scale about a as you one about was biotech that that excited is last ways that at at he This the I the nuclear one Tesla, living do what of a if years to money we to squared more a as won't two year, the of is idiocy hard. fusion last dumbest platforms to know talking technology billion, another okay? even that that
impact about can could Okay? biotech for it of And for critical at all, could make are of materials they change to sort a attacking big in be my of valuable big estimated opinion, of competitiveness world's Helion similar Synthetic deserves Tesla, In is these problems we're a we I the a the producing world. think revolution naturally on the in is world. that right? horizontal platform global in space, think same that they companies make like a higher breakthrough the can investments to our time investors SpaceX the cash and to McKinsey's If don't a addressed. what time burden electric investment which hard that easy to exciting grow vehicle, category. programmable and that Building time. nuclear U.S. into you needed, or profitability have is made a to industry successful, Biology of they're an be disease be it and challenge. biotechnology, But interest moving like sort world's rate And program. longer technologies and the we are long profitability. today to biology fusion XX% incredibly by bio but XX% companies from large report become you turn biotech is program, in will away I here, if that as a see areas environment is
of I'm a things few relatively in excited the next to take going term, year particular. in particularly but there all near that the about is are time So over
demand Ginkgo. The first at is than seeing that we're stronger ever
three planning from frankly That's we're programs. because double new platform capabilities they is scale who important what code years XX easy the give the customers an our to the of to time as ago. just task increased in-house we now year. interest might in we're their to inbound realize has R&D. able wouldn't potential to said us But base day but versus not difference get our hit programs starting that's number in Mark of want do available, this be they and Now
growth. We in established both going of a for healthy young I talked mix see at us opportunities companies come small deals pipeline that We've as a as this done deep the a create companies driver M&A large areas well M&A platform smaller we forward. year coming about two so as could both larger and and think of the months. opportunities far you'll of tuck-ins exciting on key have
like Finally, any in humble the I'd in to our to some react developed stay about throw quickly. world at us could year. given what We've confidence ability
culturally and year. I Biosecurity to as grow think ourselves evolves well we did well last Ginkgo But and prove is emerge, see will we think others quite into that them. how positioned opportunity I
develops. that People end so this I'd world the how And invest, influences slide. on when they to like it forget
for a discount we'll But think the I type that that come breakthrough long-dated runway think and capital companies of other want the at technology careful to markets term. see to much aren't And going technologies make look coming so technologies it I breakthrough an be have with I to to into scale. growth mentioned going investors the in to us breakthrough up. as are access and of near In there rising opportunity words, rates, be the for world, to these types those companies of to have companies need
really for invest investors cap And on happy to see I'm sort to while so up. see we'll the I'm your world exist. of we take the be so our excited long-term Ginkgo at we thoughtful, much. And coming should and in want think we I should Thanks minded table questions
